|
Drugs |
Target |
Type of antibody |
Half-time (days) |
Route |
Frequency
(weeks) |
Diseases treated |
| Infliximab
(Remicade®) |
TNF-α |
Mouse/human chimeric |
8-10 |
IV |
4-8 |
psoriasis [182], psoriatic arthritis [183], Crohn’s disease [184,185], ankylosing spondylitis [186,187], RA [85], ulcerative colitis [188] |
| Adalimumab
(Humira®) |
TNF-α |
Human |
10-14 |
SC |
2 |
RA [87], ankylosing spondylitis [189], psoriasis [190,191], juvenile idiopathic arthritis [192], Crohn’s disease [193] |
| Golimumab
(Simponi®) |
TNF-α |
Human |
9-15 |
SC |
4 |
psoriatic arthritis [89], ankylosing spondylitis [90], RA [93,94] |
| Certolizumab
(Cimzia®) |
TNF-α |
Pegylated Fab’ fragment of humanized MAb |
14 |
SC |
2-4 |
Crohn's disease [185,194], RA [103] |
| Etanercept
(Enbrel®) |
TNF-α |
sTNFR2-IgG1 Fc fusion |
3 |
SC |
1 |
RA [195], polyarticular JIA [196], psoriatic arthritis [197], ankylosing spondylitis [198], plaque psoriasis [199] |
|
| Table 1: FDA-approved drugs targeting TNF-α and its related pathways in various diseases. Abbreviations: TNF-α, tumor necrosis factor-α; MAb, monoclonal antibody; sTNFR2, soluble tumor necrosis factor-α receptor 2; IV, intravenous; SC, subcutaneous; RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis. |